Literature DB >> 35996028

Association of immunological parameters with aortic dilatation in giant cell arteritis: a cross-sectional study.

Philipp Jud1, Nicolas Verheyen2, Martin H Stradner3, Christian Dejaco3,4, Dieter Szolar5, René Thonhofer6, Leyla Schweiger7, Marianne Brodmann7, Franz Hafner7.   

Abstract

Aortic dilatation (AD) occurs in up to 30% of patients with giant cell arteritis (GCA). Reliable biomarkers for AD development, however, are still absent. The aim of this exploratory study was to evaluate whether immunological parameters are associated with the occurrence of AD in GCA. Cross-sectional study on 20 GCA patients with AD, 20 GCA patients without AD, and 20 non-GCA controls without AD measuring leukocytes, neutrophils, lymphocytes, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum amyloid A (SAA), interferon (IFN)-α, IFN-γ, IFN-γ-induced protein 10 (IP-10), interleukin (IL) 5, IL-8, IL-10, IL-17A, IL-18, IL-1 receptor antagonist, tumor necrosis factor (TNF)-α, platelet-derived growth factor (PDGF), L-selectin, P-selectin, and soluble intercellular adhesion molecule 1 (sICAM-1). AD was measured by aortic contrast-enhanced computed tomography and defined by enlargement of the aorta above population-based aortic diameters adjusted by age, gender, and body surface area. No significant differences were observed between GCA patients with AD and GCA patients without AD concerning levels of leukocytes, neutrophils, lymphocytes, CRP, ESR, SAA, IL-8, IL-18, PDGF, IP-10, selectins, and sICAM-1. Values of IFN-α, IFN-γ, IL-5, IL-10, IL-17A, IL-1 receptor antagonist, and TNF-α were all below the detection limits in more than 70% of subjects. Lymphocytes and CRP revealed positive correlations with the diameter of the thoracic descending aorta. Immunological parameters were not useful to conclude on the presence of AD in GCA. Further studies are required to test if CRP and lymphocytes may be useful to predict future development of AD in GCA.
© 2022. The Author(s).

Entities:  

Keywords:  Aorta; Cytokines; Giant cell arteritis; Inflammation; Interleukins

Year:  2022        PMID: 35996028     DOI: 10.1007/s00296-022-05186-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  34 in total

1.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

Review 2.  A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods.

Authors:  B Burja; T Kuret; S Sodin-Semrl; K Lakota; Ž Rotar; R Ješe; K Mrak-Poljšak; P Žigon; G G Thallinger; J Feichtinger; S Čučnik; M Tomšič; S Praprotnik; A Hočevar
Journal:  Autoimmun Rev       Date:  2017-11-28       Impact factor: 9.754

Review 3.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

4.  Incidence and predictors of thoracic aortic damage in biopsy-proven giant cell arteritis.

Authors:  M J Koster; C S Crowson; C Labarca; K J Warrington
Journal:  Scand J Rheumatol       Date:  2020-09-17       Impact factor: 3.641

5.  Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid A.

Authors:  Lorraine O'Neill; Peadar Rooney; Danielle Molloy; Mary Connolly; Jennifer McCormick; Geraldine McCarthy; Douglas J Veale; Conor C Murphy; Ursula Fearon; Eamonn Molloy
Journal:  Arthritis Rheumatol       Date:  2015-09       Impact factor: 10.995

6.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

7.  Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.

Authors:  Dirk M Nuenninghoff; Gene G Hunder; Teresa J H Christianson; Robyn L McClelland; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2003-12

8.  Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients.

Authors:  Ana García-Martínez; José Hernández-Rodríguez; Pedro Arguis; Pilar Paredes; Marta Segarra; Ester Lozano; Carlos Nicolau; José Ramírez; Francesc Lomeña; Miguel Josa; Francesca Pons; Maria C Cid
Journal:  Arthritis Rheum       Date:  2008-03-15

Review 9.  Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis.

Authors:  Sarah Louise Mackie; Elizabeth M A Hensor; Ann W Morgan; Colin T Pease
Journal:  Ann Rheum Dis       Date:  2012-12-22       Impact factor: 19.103

10.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

Authors:  Joanna C Robson; Amit Kiran; Joe Maskell; Andrew Hutchings; Nigel Arden; Bhaskar Dasgupta; William Hamilton; Akan Emin; David Culliford; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.